• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ASCO: Bristol Myers unveils I-O triplet data in melanoma as Iovance touts...

cafead

Administrator
Staff member
  • cafead   May 23, 2024 at 09:52: PM
via For the first time, investigators have revealed clinical trial performance for a triplet containing Bristol Myers’ PD-1/LAG-3 combo Opdualag and the CTLA4 inhibitor Yervoy in advanced melanoma. The three-drug regimen shrank tumors in 27 of 46 first-line melanoma patients.

article source
 

<